会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
    • 用于局部和口服载体复合活性剂的非离子非水性载体
    • US20070036843A1
    • 2007-02-15
    • US11341016
    • 2006-01-27
    • Jane HirshRoman RariyMark TrumboreAlison FlemingMark Hirsh
    • Jane HirshRoman RariyMark TrumboreAlison FlemingMark Hirsh
    • A61K9/70A61K9/22
    • A61K31/4402A61K9/006A61K9/5026A61K31/137A61K47/585
    • An improved controlled release composition for non-parenteral administration of active agents and other therapeutics, particularly for oral or topical administration, has been developed. The composition is made by dispersing a complex formed of an active agent bound to an ion-exchange resin or to another form of resin or carrier, in a non-ionic non-aqueous (“NINA”) vehicle. The complexes are optionally coated with one or more layers of coating material to provide a controlled pattern of release of active agent from the carrier. Replacing the usual aqueous vehicle with a NINA vehicle, such as an oil or an ointment, allows the active agent-carrier complexes, with or without coatings, to be both orally and topically administered. The compositions can be formulated as powders, liquids, liquid suspensions, gels, capsules, soft gelatin capsules, tablets, chewable tablets, topical ointments, lotions, pourable or pumpable fluids, semisolid, crushable tablets, and unit-of-use sachets or capsules for reconstitution or direct application. The combination of multiple active agents is possible with this system, in which one or more active agents are bound to particles and one or more active agents are dissolved or dispersed in the NINA vehicle. This allows the combination of two or more active agents, which are otherwise incompatible, into a single dosage form.
    • 已经开发了用于非肠胃外给药活性剂和其它治疗剂,特别是用于口服或局部给药的改进的控释组合物。 该组合物通过在非离子非水(“NINA”)载体中分散由与离子交换树脂结合的活性剂形成的络合物或另一种形式的树脂或载体。 复合物任选地涂覆有一层或多层涂层材料,以提供活性剂从载体中释放的受控模式。 用诸如油或软膏的NINA载体代替普通的水性载体,允许具有或不具有涂层的活性剂 - 载体复合物均经口和局部施用。 组合物可以配制成粉末,液体,液体悬浮液,凝胶,胶囊,软明胶胶囊,片剂,咀嚼片,局部软膏,洗剂,可倾倒或可泵送的液体,半固体,可压碎片剂和单位使用的小袋或胶囊 用于重组或直接应用。 该系统可以使用多种活性剂的组合,其中一种或多种活性剂与颗粒结合,一种或多种活性剂溶解或分散在NINA载体中。 这允许将两种或更多种否则不相容的活性剂组合成单一剂型。
    • 7. 发明申请
    • Topical Delivery with a Carrier Fluid
    • 带载体流体的局部输送
    • US20070036731A1
    • 2007-02-15
    • US11464100
    • 2006-08-11
    • Jane HirshRonald GurgeMark HirshMark Trumbore
    • Jane HirshRonald GurgeMark HirshMark Trumbore
    • A61K31/7034A61K9/14A61K31/496A61K31/4178A61K31/4196
    • A61K47/34A61K9/0014A61K9/12A61K31/4178A61K31/4196A61K31/496A61K31/7034A61K47/02
    • Aerosol spray formulations capable of delivering high concentrations of active agent-containing materials and/or excipient are described herein. The formulation contains a carrier fluid, a propellant, and a therapeutic, prophylactic, consmeticeutical and/or inert solid suspended, dissolved, or dispersed in the formulation. The active ingredient may be any pharmaceutically active agent, but is preferably an antibiotic, an antihistamine, an anesthetic, an anti-inflammatory, and/or an astringent. In one embodiment, the active agent is an antifungal agent. In another embodiment, the active agent is a consmeticeutical. The active agent can optionally be dispersed on, or associated with, a carrier powder. The carrier fluid is a highly volatile silicone liquid, which evaporates in less than 10 minutes, preferably less than 5 minutes, after application of the formulation to the patient's skin. The formulation may also contain one or more pharmaceutically acceptable excipients such as antioxidants, stabilizers, perfumes, colorants, viscosifiers, emulsifiers, surfactants, and combinations thereof. The formulation can be packaged in a conventional aerosol spray can.
    • 本文描述了能够递送高浓度的含活性剂的物质和/或赋形剂的气溶胶喷雾制剂。 制剂含有悬浮,溶解或分散在制剂中的载体流体,推进剂和治疗性,预防性,依赖性和/或惰性固体。 活性成分可以是任何药物活性剂,但优选为抗生素,抗组胺剂,麻醉剂,抗炎剂和/或收敛剂。 在一个实施方案中,活性剂是抗真菌剂。 在另一个实施方案中,活性剂是一种辅助药。 活性剂可以任选地分散在载体粉末上或与载体粉末相关联。 载体流体是高度挥发性的有机硅液体,其在将制剂施用于患者皮肤后在少于10分钟,优选少于5分钟内蒸发。 制剂还可以含有一种或多种药学上可接受的赋形剂,例如抗氧化剂,稳定剂,香料,着色剂,增粘剂,乳化剂,表面活性剂及其组合。 该制剂可以包装在常规的气溶胶喷雾罐中。
    • 8. 发明授权
    • Compositions containing both sedative and non-sedative antihistamines and sleep aids
    • 含有镇静和非镇静抗组胺药和睡眠辅助剂的组合物
    • US07585520B2
    • 2009-09-08
    • US10943311
    • 2004-09-17
    • Mark HirshJane HirshWhe-Yong Lo
    • Mark HirshJane HirshWhe-Yong Lo
    • A61K9/24A61K9/20A61K9/22A61K9/28A61K9/14
    • A61K45/06A61K9/209A61K9/5084A61K31/00A61K2300/00
    • Compositions containing both a sedative compound and a non-sedative antihistamine are provided. More particularly, compositions for administration at bedtime containing a sedating antihistamine or other sedating compound in immediate release form and a non-sedating antihistamine in delayed-release form are described. Alternatively, a composition, for administrating upon awakening, containing a non-sedating antihistamine in immediate release form, and a sedating antihistamine or other sedative in delayed-release form is described. Methods of inhibiting the release of histamines by administration of the compositions to a mammalian subject are also provided. The dosage forms may comprise other medications, such as leukotriene receptor antagonists, to enhance the suppression of histamine symptoms.
    • 提供了含有镇静化合物和非镇静抗组胺剂的组合物。 更具体地,描述了在睡前给药的组合物,其含有立即释放形式的镇静抗组胺药或其他镇静化合物和延迟释放形式的非镇静抗组胺药。 或者,描述了用于在觉醒时施用含有立即释放形式的非镇静抗组胺剂的组合物,以及缓释形式的镇静抗组胺药或其他镇静剂。 还提供了通过将哺乳动物受试者施用组合物来抑制组胺释放的方法。 剂型可以包含其他药物,例如白三烯受体拮抗剂,以增强组胺症状的抑制。
    • 9. 发明申请
    • Non-flammable topical anesthetic liquid aerosols
    • 不易燃的局部麻醉液体气溶胶
    • US20050123484A1
    • 2005-06-09
    • US10956819
    • 2004-10-01
    • Jane HirshDonald TibbettsMark Hirsh
    • Jane HirshDonald TibbettsMark Hirsh
    • A61K9/12A61K31/00A61K31/24A61K31/245A61K45/06A61P23/02A61L9/04
    • A61K31/245A61K9/12A61K31/00A61K31/24A61K45/06A61K2300/00
    • A topical liquid aerosol formulation for accurate metered dose delivery has been developed which includes a concentrate comprising a local anesthetic in a non-alcohol solvent and a hydrofluorocarbon (HFC) propellant. In the preferred embodiment, the concentration of the non-alcohol solvent in the concentrate is between about 75% and 85% by weight of the formulation. In the most preferred embodiment, the non-alcohol solvent is a water-soluble polyol such as ethylene glycol, propylene glycol, glycerol, diethylene glycol, dipropylene glycol, oligoalkylene glycols, liquid polyalkylene glycols, or combinations thereof. In one embodiment, the concentration of the local anesthetic in the concentrate is between about 15% and 25% by weight. In the preferred embodiment, the hydrofluorocarbon propellant is 1,1,1,2-tetrafluoroethane 1,1,1,2,3,3,3-heptafluoropropane or combinations thereof, in a concentration between about 35% and 65% by weight of the final formulation, more preferably between about 45% and 55% by weight of the final formulation. A particularly preferred formulation includes benzocaine, tetracaine, and butylaminobenzoate, wherein the concentration of benzocaine in the concentrate is 14% by weight, the concentration of tetracaine in the concentrate is 2% by weight, and the concentration of butylaminobenzoate in the concentrate is 2% by weight. It has been found that the formulation is more stable in the substantial absence of oxygen. The formulation is preferably administered using a metered dose device for release of a controlled amount of the local anesthetic.
    • 已经开发了用于精确计量剂量递送的局部液体气溶胶制剂,其包括在非醇溶剂中的局部麻醉剂和氢氟烃(HFC)推进剂的浓缩物。 在优选的实施方案中,浓缩物中非醇溶剂的浓度为制剂重量的约75%至85%。 在最优选的实施方案中,非醇溶剂是水溶性多元醇,例如乙二醇,丙二醇,甘油,二甘醇,二丙二醇,低聚亚烷基二醇,液体聚亚烷基二醇或其组合。 在一个实施方案中,浓缩物中局部麻醉剂的浓度为约15重量%至25重量%。 在优选的实施方案中,氢氟烃推进剂是1,1,1,2-四氟乙烷1,1,1,2,3,3,3-七氟丙烷或其组合,其浓度为约35-65重量% 最终制剂,更优选为最终制剂重量的约45%至55%。 特别优选的制剂包括苯佐卡因,丁卡因和丁基氨基苯甲酸酯,其中浓缩物中苯佐卡因的浓度为14重量%,浓缩物中丁卡因的浓度为2重量%,浓缩物中丁基氨基苯甲酸酯的浓度为2重量% 重量。 已经发现,在基本不存在氧的情况下,制剂更加稳定。 制剂优选使用计量剂量装置施用以释放受控量的局部麻醉剂。
    • 10. 发明申请
    • Topical aerosol foams
    • 局部气溶胶泡沫
    • US20060188449A1
    • 2006-08-24
    • US10565346
    • 2004-10-04
    • Jane HirshJohn WillisMark Hirsh
    • Jane HirshJohn WillisMark Hirsh
    • A61K31/573A61L9/04A61K31/56A61K31/24
    • A61K31/24A61K9/0014A61K9/122A61K9/124A61K31/56A61K31/573
    • A stable topical aerosol foam is provided. The foam-forming formulation includes a HFA propellant and an active agent in an emulsion. The emulsion has an oil phase and an aqueous, i.e. water-containing, phase. The active agent may be present in either phase or dispersed in the emulsion. The oil phase may consist at least in part of the HFA propellant. Either or both of the oil phase and the aqueous phase may contain one or more surfactants, emulsifiers, emulsion stabilizers, buffers, and other excipients. In an alternative embodiment, the aqueous phase contains a water-soluble active agent, for example, a local anesthetic, and the oil phase contains a water-insoluble second active agent. The foam is stable on the skin, for example for at least 10 minutes at body temperature, and will disappear into the skin upon rubbing or after prolonged standing. The formulation has the advantage of an inert non-flammable hydrofluorocarbon propellant without requiring the use of additional co-solvents or co-propellants. The composition is administered to the skin or mucous membranes.
    • 提供稳定的局部气溶胶泡沫。 泡沫形成制剂包括HFA推进剂和乳液中的活性剂。 乳液具有油相和含水相,即含水相。 活性剂可以以任一相存在或分散在乳液中。 油相可以至少部分地由HFA推进剂组成。 油相和水相中的任一种或两者可以含有一种或多种表面活性剂,乳化剂,乳液稳定剂,缓冲剂和其它赋形剂。 在另一个实施方案中,水相含有水溶性活性剂,例如局部麻醉剂,油相含有水不溶性第二活性剂。 泡沫在皮肤上是稳定的,例如在体温下至少10分钟,并且在摩擦或长时间放置后将消失在皮肤中。 该配方具有惰性不易燃氢氟烃推进剂的优点,而不需要使用额外的共溶剂或共推进剂。 将组合物施用于皮肤或粘膜。